Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

The average weight increase after 52 weeks for Wegovy patients was 2 pounds, whereas Zepbound patients gained 11 pounds. Eli ...

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S.

Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...

The company studied Orforglipron for weight maintenance over 52 weeks in patients who were on 72 weeks of popular injectable ...

CNBC's Annika Kim Constantino reports on Eli Lilly after the company said its closely watched obesity pill helped patients ...

Eli Lilly’s oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.

Lilly’s Attain-Maintain Phase III results show that the oral GLP-1 orforglipron can effectively preserve weight loss after injectable therapy, positioning it as a potential long-term maintenance ...